South Africa Initiates 55,123 People on Twice-Yearly Lenacapavir PrEP

The South Africa lenacapavir PrEP rollout has initiated 55,123 people in its first 94 days, the Department of Health said on 8 September 2026. The tally, counted as of 7 September, is the first official three-month figure since President Cyril Ramaphosa and Health Minister Dr Aaron Motsoaledi launched the twice-yearly injection at Lillian Ngoyi Stadium in Secunda, Mpumalanga, on 5 June 2026.

The department described the number as evidence of “strong demand for this long-acting HIV prevention option.” Lenacapavir is offered inside a comprehensive PrEP-choice programme, not as a standalone product. SAHPRA has registered the medicine as safe and effective for HIV prevention after reviewing preclinical, clinical and manufacturing data. Healthcare workers and implementing partners are tracking uptake, commodity availability, quality of service, client follow-up and safety. The first public recipient was 21-year-old Jane Mndebele, injected by the Minister at the launch. South Africa was the ninth African country to introduce lenacapavir into a national programme.

South Africa lenacapavir PrEP: where the initiations are happening

Gauteng and KwaZulu-Natal account for 69.5% of all starts. That geography matches both clinic density in phase one and the burden of new infections. Mpumalanga, the launch province, sits fifth of six, a reminder that ceremony and volume are not the same thing.

Ad

Source: Department of Health, cited by SAnews, 8 September 2026. Shares calculated from reported counts.

A deliberately narrow first phase

Phase one is deliberately narrow: 360 public facilities, roughly 8% of public clinics, across 24 high-burden districts in six provinces. Priority groups include adolescent girls and young women, pregnant and breastfeeding women, female sex workers, men who have sex with men, transgender people and people who inject drugs. The 71% female share, and the department’s note that most of those women are pregnant or breastfeeding, fits that targeting and the PURPOSE-1 evidence generated in young women in South Africa and Uganda.

Lenacapavir sits alongside oral PrEP, condoms, voluntary medical male circumcision, treatment as prevention and behavioural programmes. Ramaphosa was explicit at launch: “It is one more powerful tool in our arsenal.” Early operational data presented around AIDS 2026 found that 98.5% of HIV-negative people offered a choice between the daily pill and the six-monthly injection chose the injection. Access teams should treat that as durable demand, not anecdote.

The President announced the intention in the 2026 State of the Nation Address and launched the programme less than four months later. Combined catalytic funding of R1.3 billion from the Global Fund and the Children’s Investment Fund Foundation, alongside government budget, underwrites phase one. National targets remain close to one million people by end-2027 and three million within three years.

Demand is outrunning branded supply

The 55,123 figure is a success metric only if you read it against the supply envelope. Gilead Sciences remains the sole manufacturer. The Global Fund has pledged 974,450 branded doses over two years, enough to start and keep about 456,000 people on two doses a year. Deliveries reported through mid-year stood at 115,320 doses. Business Day, citing the department in early September, put distributed stock at 88,000 doses and administered doses at 46,233 a week before the 55,123 initiation print. The two snapshots are consistent with a steep late-August acceleration.

South Africa is paying about USD 60 per person per year for Global Fund-procured branded lenacapavir. Licensed generics, from six manufacturers in Egypt, India and Pakistan under Gilead’s royalty-free licences covering 120 low- and middle-income countries, are expected on the market in the second half of 2027 at around USD 40 per person per year. Hetero has already filed a generic dossier with SAHPRA. Minister Motsoaledi has pressed publicly for a seventh, South African voluntary licence, and SANAC opened an expression-of-interest process earlier in 2026 with Unitaid and USP support. Free State, Limpopo and Northern Cape enter only when generics and phase two procurement widen the envelope; the department points to April 2027 as the phase two hinge.

At roughly 586 starts a day, phase one is converting scarce branded stock into use. First recipients come due for their second dose from 6 December 2026. Until then, initiation volume can look healthier than the programme’s true carrying capacity. Retention, not first-dose demand, is the next leading indicator.

Why the product cleared the access bar

Lenacapavir is a first-in-class HIV capsid inhibitor given as a subcutaneous injection every six months after an initiation sequence. PURPOSE-1, run in adolescent girls and young women in South Africa and Uganda, originally reported zero incident infections on lenacapavir against oral PrEP comparators. PURPOSE-2, in men and gender-diverse people, reported a 96% reduction in HIV risk against background incidence. Extended follow-up presented at CROI 2026 identified a small number of additional acquisitions despite on-time injections, still leaving incidence far below oral PrEP and background rates. Safety findings have been dominated by manageable injection-site reactions. Pregnancy and lactation data from the development programme formed part of the public-sector case for prioritising those groups.

That evidence package is why SAHPRA registration, Global Fund procurement and a presidential launch could be compressed into the same calendar window as high-income approvals, an unusually short North-to-South lag for a prevention technology.

What the numbers mean for access leaders

The public-health gap remains large. South Africa is still the epicentre of the epidemic, with about 8.15 million people living with HIV (12.9% of the population) and adult (15-49) prevalence near 18.1%, per figures the department cited in June 2026. New infections in recent official and modelled estimates sit between 134,000 and 180,000 a year, depending on the year and source. The reference model for access teams is HE2RO (Wits), led by Lise Jamieson: covering about 1.7 million people a year with lenacapavir could push annual new infections toward roughly 65,000 by the early 2040s, while an optimistic 2.9 million a year could move incidence faster toward the “end AIDS as a public-health threat” threshold. Phase one’s 456,000-person branded envelope is a start, not the modelled scale.

The economic argument is shifting from efficacy to unit cost and delivery. Efficacy is no longer the contested variable. What is contested now: landed cost after generics; whether a South African manufacturer wins a licence and can produce at quality and volume; clinic throughput and follow-up systems for a twice-yearly schedule; and how lenacapavir is costed against averted lifetime ART, vertical transmission and hospitalisation. At USD 40-60 per person-year, the product sits in a range where health-economic models are more sensitive to targeting accuracy than to list price. Poor targeting wastes a scarce prevention asset. Good targeting, aimed at pregnant women, adolescent girls and young women in high-incidence districts and key populations, is where the incremental cost-effectiveness ratio compresses.

Choice architecture is working; capacity may not be. A 98.5% preference for the injection among people offered a real choice is rare in prevention programmes. It undercuts the “adherence will save us” assumption that has dogged daily oral PrEP. It also concentrates operational risk on injection-site workflow, appointment systems for month six, and commodity security. Wits RHI’s LEN4PrEP implementation study reported 85% on-time return for the second dose in a small early cohort, which is encouraging but not yet national.

Local production is an industrial-policy play as much as a health play. A seventh licence on South African soil would not change 2026 volumes. It would change 2028-2030 supply security, regional export potential, and the politics of paying for lenacapavir from the domestic budget once Global Fund catalytic stock tapers. That is the file government affairs, pricing and market-access teams should be working now, not after the first generic award.

What to watch through mid-2027

The December 2026 second-dose wave. How many June starters return on time is the first real test of long-acting PrEP as a public-sector product rather than a launch event.

SAHPRA generic reviews. Hetero’s filing is the marker; first approval timing will set the 2027 tender calendar.

Phase two geography (April 2027). Free State, Limpopo and Northern Cape entry, and any widening beyond the original 360 sites.

The South African voluntary licence. Whether Gilead grants a seventh licence, to whom, and on what volume and export terms.

Safety and pregnancy outcomes in routine use. The department has framed pharmacovigilance as a standing obligation. Any serious-event cluster will travel faster than the 55,123 success number.

The domestic budget transition. Minister Motsoaledi has said South Africa intends to fund the programme independently, with donor help, after the first branded tranche. Watch the 2027 Estimates of National Expenditure and any transversal contract design under the 2026 procurement regulations.

Source

Department of Health / SAnews, “Over 55 000 people initiated on groundbreaking Lenacapavir,” 8 September 2026, sanews.gov.za.